CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine
Requires Refrigeration
Intramuscular (IM) gluteal
Manufacturer # 49702025315
Brand CABENUVA
Manufacturer Glaxo Specialty
Country of Origin Unknown
Application HIV Integrase Inhibitor and HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor
Container Type Single-Dose Kit
Dosage Form Injection
Generic Drug Name Cabotegravir / Rilpivirine
Is_Active_Vendor Y
Is_DSCSA Y
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag N
NDC Number 49702025315
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 90 days
Storage Requirements Requires Refrigeration
Strength 400 mg - 600 mg
Supplier_ID 488095
Type Intramuscular
UNSPSC Code 51343800
Volume 2 mL - 2 mL
